Home / CLINICIANS / Clinical Evidence / PAD III
USA / International

A Superior Strategy
For Calcified PAD

IVL provides superior vessel prep and excellent long-term results in calcified vessels while preserving future treatment options

Watch Dr. Bill Gray’s Presentation of the Late-Breaking Data
data
Watch Presentation
Read the JACC Publication
data
Download
PAD III Data
Summary
data
Download Data Summary
Download

Shockwave IVL Symposium at VIVA20:
Insights from the DISRUPT PAD III RCT in Severe Calcium

Key Findings

  • In the largest-ever randomized clinical trial of severely calcified peripheral lesions, IVL demonstrates superiority over PTA
  • IVL demonstrates a significant reduction in dissections and provisional stenting versus PTA
  • IVL achieves superior vessel preparation vs. PTA with lower pressure, fewer stents, less need for post-dilatation and fewer dissections
  • Disrupt PAD III randomized data confirm the consistent safety and effectiveness of IVL from previous studies in multiple vessel beds
device

In the Largest-Ever Randomized Study of Severely Calcified Peripheral Lesions, IVL Demonstrates Superiority over PTA

306
SFA/Popliteal lesions
randomized to IVL or PTA
83%
Severe calcification by PARC by
an independent core-lab*
129mm
Average calcified length
by an independent core-lab*
*Data refer to IVL arm of randomized study
Primary Endpoint - Site Reported and Angiographic Core Lab Procedure Success Percentage Chart

IVL achieves superior vessel preparation with lower pressure, fewer stents, less need for post-dilatation and fewer dissections

44%
Lower pressure to achieve better results with IVL versus PTA
75%
Reduction in provisional stent placement risk with IVL versus PTA
69%
Reduction in need for post-dilation versus PTA
79%
Reduction in Grade D Dissection with IVL versus PTA

Disrupt PAD randomized data confirm the consistent safety and effectiveness of IVL from previous studies in multiple vessel beds

Diameter Stenosis and Final Angiographic Outcomes Charts

Ready to Make Waves with Shockwave IVL?

Looking for careers? Click here.

ico email Connect

We're excited about IVL's potential in aortic stenosis, too!

But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.

MORE ON TAVR ENABLING TRANSFEMORAL ACCESS
SIGN UP FOR UPDATES ON OUR VALVE R&D PROGRAM

Get Crackin' with Shockwave IVL Today

Thanks for contacting us! We will get in touch with you shortly.